Topic: Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy

Oct 2021 | Assessment

Interventions of Interest: Mavacamten (MyoKardia and Bristol-Myers Squibb) Hypertrophic cardiomyopathy (HCM) is a disorder of the heart due to dysfunction of the sarcomeres in cardiac muscle cells (myocytes). Sarcomeres are cellular structures that are critical in myocyte contraction. The sarcomere dysfunction in HCM can lead to hypertrophy (thickening) of the heart. HCM can be due […]